FDA has approved the trade name Firmagon for degarelix for injection, a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of advanced prostate cancer. “This ...

New Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist Demonstrates Rapid, Long-term Suppression of Testosterone - a hormone that stimulates prostate cancer growth. PARSIPPANY, N.J., Dec. 24 ...

ORLANDO—Prostate cancer (PCa) patients treated with degarelix have a lower risk of PSA failure or death compared with those treated with leuprolide, according to the findings of a long-term study. The ...

Degarelix is a new hormonal therapy from the GnRH receptor blocker class of agents that immediately blocks the GnRH receptor and achieves fast testosterone suppression without an initial surge. In the ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hgtc2g/firmagon) has announced the addition of GlobalData's new report ...

Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group Premenopausal women with ...

...ALP suppression was significantly greater in the degarelix group than in the leuprolide group... Gonadotropin-releasing hormone (GnRH) receptor agonists, such as leuprolide, are the most commonly ...

Pooled data from five phase III studies of men with prostate cancer (n = 1,925) confirm that androgen deprivation therapy (ADT) with degarelix, a gonadotropin-releasing hormone antagonist, offers ...

Ferring Pharmaceuticals, USA today received approval from the U.S. Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist, ...

CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...